Study guide
11.3 Oncology Imaging Procedures
Certified Nuclear Medicine Technologist CNMT
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current CNMT Exam Facts 1.2 How to Use This Guide
2 Radiation Physics Fundamentals
2.1 Radioactive Materials, Isotopes, and Decay Modes 2.2 Decay Calculations and Counting Statistics 2.3 Interactions of Radiation with Matter 2.4 Radiation Detector Types and Principles
3 Biological Effects & ALARA
3.1 Biological Effects of Radiation Exposure 3.2 ALARA and Protection Calculations 3.3 Dose Limits, Surveys, and Personal Monitoring
4 NRC & Regulatory Compliance
4.1 NRC Areas, Spills, Waste, and Records 4.2 Written Directives and DOT Shipping 4.3 EPA, OSHA, HIPAA, FDA, and USP Standards 4.4 Radioactive Waste Disposal and Regulatory Records
5 Generators & Kit Preparation
5.1 Radionuclide Generators and Quality Control 5.2 Radiopharmaceutical Kit Preparation 5.3 Radiopharmaceutical Quality Control
6 Tc-99m Diagnostic Agents
6.1 Tc-99m Cardiac Imaging Agents 6.2 Tc-99m Bone, Renal, and GU Agents 6.3 Tc-99m GI and Hepatobiliary Agents 6.4 Tc-99m CNS, Infection, and Labeled Cells
7 Non-Tc Diagnostic & PET Agents
7.1 Iodine and Indium Diagnostic Agents 7.2 Gallium, Thallium, Xenon, and Miscellaneous Agents 7.3 PET Radiopharmaceuticals 7.4 Neurologic, Breast, and Neuroendocrine PET Agents
8 Therapeutics, Adjuncts & Administration
8.1 Therapeutic Radiopharmaceuticals 8.2 Interventional and Adjunct Pharmaceuticals 8.3 Blood Labeling and Administration Techniques 8.4 Blockade, Comfort, and Gastrointestinal Adjunct Agents
9 Non-Imaging Instrumentation
9.1 Well Counters, Probes, and Survey Meters 9.2 Dose Calibrator Quality Control 9.3 Auxiliary and Patient Care Equipment
10 Imaging Systems & Quality Control
10.1 Gamma Camera Quality Control 10.2 SPECT and SPECT/CT Systems 10.3 PET and PET/CT Systems and QC 10.4 CT Systems, PACS, and Information Systems 10.5 CT Radiation Dose, Safety Alerts, and Protocol Optimization
11 Pulmonary, Bone, Oncology & Infection Imaging
11.1 Pulmonary Imaging Procedures 11.2 Bone and Musculoskeletal Imaging 11.3 Oncology Imaging Procedures 11.4 Infection Imaging Procedures
12 Renal, Endocrine & Hematopoietic Imaging
12.1 Renal and Genitourinary Imaging 12.2 Endocrine Imaging (Thyroid, Parathyroid, Adrenal) 12.3 Hematopoietic and Bone Marrow Imaging 12.4 Thyroid Uptake Measurement and Radioiodine Survey Technique
13 Cardiovascular Procedures
13.1 Myocardial Perfusion Imaging 13.2 Cardiac Function, Viability, and Special Studies 13.3 Exercise and Pharmacologic Stress Testing
14 GI, CNS, Therapy & Hybrid CT Procedures
14.1 Gastrointestinal Procedures 14.2 Central Nervous System Procedures 14.3 Radionuclide Therapy Procedures 14.4 CT and Hybrid Imaging in Nuclear Medicine 14.5 CSF Studies: Cisternography, Leak Localization, and Shunt Patency
15 Patient Care & Clinical Workflow
15.1 Patient Care, Education, and Consent 15.2 Scheduling and Radiopharmaceutical Procurement 15.3 Acquisition, Positioning, and Image Quality 15.4 Image Processing and Quantitative Analysis 15.5 Non-Imaging Studies: Specimens, Counting, and Error Analysis
11.3 Oncology Imaging Procedures
Key Takeaways Explain This Topic AI
Oncology NM includes Ga-67 tumor imaging, receptor/peptide agents, molecular breast imaging, lymphoscintigraphy/sentinel node mapping, and PET tumor tracers
Sentinel node mapping uses filtered Tc-99m sulfur colloid or Tc-99m tilmanocept (Lymphoseek®, CD206 binding) with intradermal/interstitial injection and sequential imaging ± probe
FDG PET/CT is the workhorse: whole-body or skull-base-to-mid-thigh FOV; melanoma often needs true vertex-to-toes coverage
Specialized PET: PSMA agents for prostate cancer and Ga-68/Cu-64 Dotatate for somatostatin-receptor neuroendocrine tumors
FDG patient prep emphasizes fasting (~4–6 h), controlled glucose, rest after injection, and timed uptake (~60 min typical) to avoid muscle and brown-fat artifacts
Last updated: August 2026
11.3 Oncology Imaging Procedures
Quick Answer: Know Ga-67 tumor imaging, peptide/receptor scans, molecular breast imaging , sentinel node (filtered SC / tilmanocept ), and PET ( FDG , PSMA , Dotatate ) with correct FOV , prep , and timing .
Ga-67 Tumor Imaging
Ga-67 citrate binds transferrin and localizes in some tumors (classic teaching: lymphoma, selected other malignancies) and infection/inflammation. Physical t½ ≈ 78 h; principal gammas include ~93, 185, and 300 keV—use appropriate multi-energy windows and medium-energy collimation.
- Item Teaching practice
- Adult activity Often ~5–10 mCi IV (protocol-dependent)
- Imaging times Commonly 48–72 h (sometimes earlier/later sets)
- Biodistribution Liver, spleen, bone marrow, bowel, lacrimal/nasopharynx—bowel prep may be used
- Modern context Largely replaced by FDG PET for many tumors, but still testable
Bowel activity is a classic pitfall—delayed imaging, SPECT, and clinical correlation help.
Peptide / Receptor Imaging (Overview)
Receptor-targeted agents map tumors expressing specific surface targets:
Target / class Example agents (teaching) Typical use
Somatostatin receptors (SSTR) In-111 pentetreotide (Octreoscan®); Ga-68/Cu-64 DOTATATE PET Neuroendocrine tumors
- PSMA F-18/Ga-68 PSMA PET agents Prostate cancer staging/recurrence
- Other peptides Protocol-specific investigational/clinical agents Selected solid tumors
Tech points: verify correct agent and energy settings; hydrate; time imaging to package insert/SOP (In-111 pentetreotide often 4 and 24 h class; Dotatate PET ~45–90 min class). Know that cold somatostatin analogs (octreotide therapy) may need holding per protocol before SSTR imaging.
Molecular Breast Imaging (MBI)
Molecular breast imaging (also related historically to BSGI) uses a breast-specific gamma camera and typically Tc-99m sestamibi . The patient is positioned with gentle compression; each breast is imaged in standard projections. Indications include dense breasts, problem-solving after mammography, and selected high-risk evaluations—not a replacement for screening mammography in average-risk populations.
- Item Notes
- Agent Tc-99m sestamibi (typical adult ~20–30 mCi class—follow protocol)
- Injection Preferably contralateral arm to the breast of concern when possible
- Timing Begin imaging ~5–10+ min after injection per SOP
- Trap Infiltration or wrong-side injection confounds interpretation
- Lymphoscintigraphy and Sentinel Node Mapping
Goal: identify the first draining lymph node(s) for surgical probe-guided biopsy (breast, melanoma, other).
- Tracer Mechanism / notes
- Filtered Tc-99m sulfur colloid Smaller particles enter lymphatics from interstitial injection
- Tc-99m tilmanocept (Lymphoseek®) Binds mannose receptors (CD206) on reticuloendothelial cells in nodes
Injection technique: intradermal, subdermal, peritumoral, or areolar protocols per surgeon/lab— not standard IV. Activity is low (often ~0.5–1 mCi class total, protocol-specific). Image injection site and drainage basins dynamically/static; mark skin as ordered; provide images/probe counts for the OR. Contamination at the skin and shine-through from the injection site are major pitfalls—use shielding, transmission markers, and careful positioning.
- PET Tumor Imaging
- FDG PET/CT — General Principles
F-18 FDG is a glucose analog trapped in cells with high glycolysis (many malignancies, infection, inflammation, brain, heart under some conditions).
- FOV choice Typical use
- Skull base to mid-thigh Standard oncology staging for many solid tumors
True whole body (vertex to toes) Melanoma , cutaneous malignancies, myeloma surveys, search for unknown primary when ordered
Limited regional Therapy response or known single-site problem
Adult activity is often ~10–20 mCi class (weight-based common). Uptake period typically ~60 minutes (45–90 min range) in a warm, quiet room; patient rests, avoids talking/chewing to reduce muscle and laryngeal uptake.
FDG Patient Prep (High Yield)
- Rule Rationale
- Fast ~4–6 hours (water OK per protocol) Lower insulin/glucose competition
Check fingerstick glucose High glucose decreases tumor FDG uptake; extreme hyperglycemia may require reschedule per policy
- No strenuous exercise 24 h Prevents muscle uptake
- Warm waiting area Reduces brown fat FDG uptake
- Diabetes management Follow lab SOP for insulin timing—never improvises doses without protocol
- Remove metal; empty bladder Artifact and pelvic clarity
Brown fat (supraclavicular, paravertebral) and tense muscle uptake are classic false “nodes.” Document recent chemo/radiation, growth-factor therapy, and infection—they alter patterns.
PSMA PET
Prostate-specific membrane antigen ligands (Ga-68 or F-18 labeled) image prostate cancer soft-tissue and bone disease with high target contrast. Prep is agent-specific (often less stringent fasting than FDG); hydrate and void. Know it is not FDG—different biology and biodistribution (salivary, lacrimal, kidneys, bladder, bowel).
Neuroendocrine (Dotatate) PET
Ga-68 DOTATATE (and related SSTR agonists) maps somatostatin receptor –positive NETs. Imaging after appropriate uptake time; correlate with prior octreotide therapy holds. Normal intense uptake in pituitary, spleen, kidneys, adrenals, and uncinate process of pancreas can trap newcomers—know expected biodistribution at a tech level.
Oncology Procedure Comparison
- Study Primary agent class Tech focus
- Ga-67 tumor Ga-67 citrate ME collimator, 48–72 h, bowel activity
- MBI Tc-99m sestamibi Breast-specific camera positioning
- Sentinel node Filtered SC or tilmanocept Interstitial injection, mapping, probe
- FDG PET F-18 FDG Prep, glucose, FOV, 60-min uptake
- PSMA PET PSMA ligand Prostate cancer pathway, hydration
- Dotatate PET SSTR agonist NET pathway, med holds
Match cancer type → tracer → FOV → prep . That tetrad wins Domain V oncology items.
Documentation and Coordination
Oncology days often combine injection, long uptake, PET/CT acquisition, and surgeon coordination for sentinel-node cases. Document glucose, last meal time, injection site and residual syringe activity, uptake duration, and any insulin or steroid use. For receptor studies, record recent cold-analog therapy. Clear handoff notes prevent repeat injections and protect quantitative comparisons on therapy-response scans.